India Clinical Trials Market By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Treatment Studies, Observational, Expanded Access), By Indication (Autoimmune, Blood Disorders, Pain Management, Oncology, CNS Condition, Diabetes, Obesity, Cardiovascular, Others), By Location (Hospital, Laboratories, Clinics), By Company, By Region, Forecast & Opportunities, FY2026

India clinical trials market is forecasted to grow at a significant CAGR during the forecast period. The India clinical trials market is driven by increasing burden of chronic diseases in the country. In addition to this, pandemic caused due to COVID-19 in the country is resulted in high demand for developing a suitable treatment for the same. This is projected to bolster the market growth over the coming years. Also, upsurge in research and developmental activities by key market players is further expected to boost the demand through FY2026.

The India clinical trials market is segmented based on phase, study design, indication, end user, company, and region. Based on phase, the market can be segmented into Phase I, Phase II, Phase III, Phase IV. Out of which, the Phase III dominated the market until FY2020 in terms of highest market share and is further expected to maintain its lead in the market during the forecast period as well. This dominance can be attributed to the fact that it is one of the most critical phases evaluating the effectiveness of the new intervention, as well as its value in clinical practice. Phase III trials are very expensive and involves huge subjects. Also, the phase II segment is projected to register high growth in the next 5 years which can be accredited to its crucial role, especially in oncology-related studies.

The major players operating in the India clinical trials market are Pfizer India Ltd., Ѕun Рhаrmасеutісаl Іnduѕtrіеѕ Ltd., GlaxoSmithKline Pharmaceuticals Ltd., IQVIA India Pvt. Ltd., Covance Ltd., Ноffmаnn-Lа Rосhе India Ltd., Novartis India Ltd., AstraZeneca India Pvt. Limited, Pharmaceutical Product Development Ltd., Eli Lilly and Company (India) Pvt. Ltd, and others. The major market players tends to adopt various strategies including collaborations, acquisitions, new product launches and geographical expansions in order to sustain market competition.

Years considered for this report:

Historical Years: FY2016-FY2019

Base Year: FY2020

Estimated Year: FY2021

Forecast Period: FY2022–FY2026

Objective of the Study:

• To analyze and estimate the market size of India clinical trials market from FY2016 to FY2019.
• To estimate and forecast the market size of India clinical trials market from FY2020 to FY2026 and growth rate until FY2026.
• To classify and forecast India clinical trials market based on phase, study design, indication, end user, company, and regional distribution.
• To identify dominant region or segment in the India clinical trials market.
• To identify drivers and challenges for India clinical trials market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in India clinical trials market.
• To identify and analyze the profile of leading players operating in India clinical trials market.
• To identify key sustainable strategies adopted by market players in India clinical trials market.

Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the clinics, hospitals and presence of all major players across the globe.

TechSci Research calculated the market size of India clinical trials market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

• Clinical investigators
• Market research and consulting firms
• Government bodies such as regulating authorities and policy makers
• Organizations, forums and alliances related to clinical trials

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as hospitals, clinics, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, India clinical trials market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• India Clinical Trials Market, By Phase:
• Phase I
• Phase II
• Phase III
• Phase IV
• India Clinical Trials Market, By Study Design:
• Interventional
• Treatment Studies
• Observational
• Expanded Access
• India Clinical Trials Market, By Indication:
• Autoimmune
• Blood Disorders
• Pain Management
• Oncology
• CNS Condition
• Diabetes
• Obesity
• Cardiovascular
• Others
• India Clinical Trials Market, By End User:
• Hospital
• Laboratories
• Clinics
• India Clinical Trials Market, By Region:
• North
• South
• East
• West

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in India clinical trials market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).